tiprankstipranks
Advertisement
Advertisement
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
PremiumThe FlyOnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
3M ago
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
Premium
Ratings
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
3M ago
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
Premium
The Fly
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
3M ago
OnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
PremiumRatingsOnKure Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
8M ago
OnKure Therapeutics files $200M mixed securities shelf
Premium
The Fly
OnKure Therapeutics files $200M mixed securities shelf
8M ago
OnKure Therapeutics Announces Sales Agreement with Leerink
Premium
Company Announcements
OnKure Therapeutics Announces Sales Agreement with Leerink
8M ago
VTI ETF News, 10/7/2025
PremiumMarket NewsVTI ETF News, 10/7/2025
9M ago
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
Premium
Ratings
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
10M ago
OnKure Therapeutics Advances Cancer Drug Development
Premium
Company Announcements
OnKure Therapeutics Advances Cancer Drug Development
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100